Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Organogenesis Holdings Inc (NASDAQ: ORGO) was $5.20 for the day, down -2.26% from the previous closing price of $5.32. In other words, the price has decreased by -$2.26 from its previous closing price. On the day, 1.22 million shares were traded.
Ratios:
Our analysis of ORGO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 157.81. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’25 when Driscoll Michael Joseph bought 25,000 shares for $5.08 per share.
Driscoll Michael Joseph sold 25,000 shares of ORGO for $127,535 on Mar 04 ’25. The Director now owns 166,879 shares after completing the transaction at $5.10 per share. On Dec 13 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 55,615 shares for $3.36 each. As a result, the insider received 186,866 and left with 3,044,779 shares of the company.
Valuation Measures:
As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 928.57, and their Forward P/E ratio for the next fiscal year is 27.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.37 while its Price-to-Book (P/B) ratio in mrq is 2.49.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 11.48%, while the 200-Day Moving Average is calculated to be 46.49%.
Shares Statistics:
A total of 125.73M shares are outstanding, with a floating share count of 64.40M. Insiders hold about 49.24% of the company’s shares, while institutions hold 47.70% stake in the company.
Earnings Estimates
The dynamic stock of Organogenesis Holdings Inc (ORGO) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.03, with high estimates of $0.03 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.16 and $0.16 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.28, with 1.0 analysts recommending between $0.28 and $0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $93.8M to a low estimate of $87.7M. As of the current estimate, Organogenesis Holdings Inc’s year-ago sales were $109.98MFor the next quarter, 3 analysts are estimating revenue of $102.17M. There is a high estimate of $115.1M for the next quarter, whereas the lowest estimate is $94.7M.
A total of 4 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $508.6M, while the lowest revenue estimate was $450.5M, resulting in an average revenue estimate of $488.25M. In the same quarter a year ago, actual revenue was $482.04MBased on 3 analysts’ estimates, the company’s revenue will be $549.3M in the next fiscal year. The high estimate is $584.91M and the low estimate is $528M.
